Flamingo Vol. I N 3

Voo-Doo. Untitled. Prose. 1. Widow. Untitled. Prose. 1. Tiger. Untitled. Prose. 1. Purple Cow. Untitled. Prose. 1. Anonymous. Untitled. Prose. 1. Life. Untitled. Prose. 2. Yale Record. Untitled. Prose. 2. Voo-Doo. Untitled. Prose. 2. Sour Owl. Untitled. Prose. 2. Puppet. Untitled. Prose. 2. Sun Dial. Untitled. Prose. 2. Anonymous. Untitled. Prose. 2. Nottingham, Ruth. Teddy . Prose. 5. Grogan. Untitled. Picture. 7. Anonymous. Untitled. Prose. 7. Anonymous. An Easy One . Prose. 7. Anonymous. How Terrible! Prose. 7. Anonymous. Untitled. Prose. 7. Anonymous. Untitled. Poem. 7. F.H.G. Untitled. Picture. 7. Wood, J.E.F. When mother Went to College . Prose. 8. E.D.T. Chicago Corn Exchange . Poem. 8. Anonymous. Untitled. Prose. 8. Anonymous. Untitled. Poem. 8. Anonymous. All But . Prose. 8. R.D.B. Roscoe to The Rescue . Prose. 9. Leet, L.D. On The Efficacy of Dreams . Prose. 10. Orange Ade. The Fable of the Coffin Nailer . Prose. 11. Orange Ade. Time Wasted . Prose. 11. Orange Ade. The Americanized Boy . Prose. 11. Orange Ade. Anything to Oblige . Prose. 11. Orange Ade. Tit For Tat . Prose. 11. Orange Ade. Good Alibi . Prose. 11. Orange Ade. Untitled. Prose. 11. Grogan. Untitled. Picture. 11. Lusk, R.G. On The Absurdity of Catching Fish When A-Fishing . Prose. 12. Anonymous. Co-eds and Plain Eds in 1950 . Picture. 13. Potter, W.M. Letters of A Japanese Sandman . Prose. 13. Anonymous. Ex Facultate . Prose. 13. Anonymous. Untitled. Prose. 13. R.J.S. An Uplifting Influence . Picture. 13. Anonymous. Consider the Luxite Girl . Poem. 14. Anonymous. Shades of Orpheus . Poem. 14. Anonymous. With The Gospel Team . Poem. 14. Anonymous. Untitled. Prose. 14. Anonymous. Untitled. Poem. 14. Anonymous. A Dirty Trick . Prose. 14. Taylor, Elsie D. Vestigial Customs . Prose. 15. Anonymous. Untitled. Prose. 16. Anonymous. A New version of Anthropology . Prose. 18. Anonymous. A New version of Anthropology . Picture. 18. Anonymous. Untitled. Prose. 18. Funk, Dorothy K. Untitled. Picture. 18. Anonymous. A Deep one . Prose. 18. Anonymous. Take His Name . Prose. 18. Olney, Clarke. The Evolution of An Intellectual . Prose. 19. Anonymous. Untitled. Prose. 19. Anonymous. Untitled. Prose. 20. W.A.W. On Getting Up For Breakfast . Prose. 20. McCann. Untitled. Picture. 21. Anonymous. Untitled. Prose. 21. Anonymous. S.S.S. . Prose. 21. Anonymous. The Judge Disagreed . Prose. 21. Anonymous. The Modern Woman . Prose. 21. Anonymous. Denison Slang in Japan . Prose. 22. Anonymous. Being Specific . Prose. 22. Anonymous. Then The Fun Began . Prose. 22. Anonymous. Then The Fun Began . Prose. 22. Anonymous. Chess Nuts . Poem. 22. Anonymous. Chess Nuts . Picture. 22. Funk, Dorothy K. Untitled. Picture. 22. Anonymous. Untitled. Prose. 22. Reel, Virginia. Untitled. Prose. 22. Anonymous. Untitled. Prose. 23. Anonymous. Take This to Heart . Prose. 23. Anonymous. Stepping Out . Picture. 23. Olney, Clarke. Untitled. Picture. 23. Anonymous. To Lalage . Prose. 23. Anonymous. Untitled. Poem. 24. Anonymous. Description of the Day . Prose. 25. Anonymous. Untitled. Prose. 25. Voo-Doo. Good Bizziness . Prose. 26. Anonymous. Fore! . Prose. 26. Anonymous. Untitled. Prose. 26. Brelsford, Ernest C. Souveniring . Prose. 27. Anonymous. Untitled. Prose. 30. Burr. Sweet Dreams . Prose. 30. Jester. Untitled. Prose. 30. Judge. Untitled. Prose. 30. Goblin. Untitled. Prose. 30. Cracker. Sanitation . Poem. 32. Anonymous. Untitled. Prose. 32. Jester. Untitled. Prose. 32. Goblin. Untitled. Prose. 32. Record. Untitled. Prose. 32. Linotype. Untitled. Prose. 32. Holt, Kilburn. The Schemer\u27s Lament . Poem. 7. Owen, Ernest t. Mother . Poem. 3. Owen, Ernest T. To--- . Poem. 24

Effectiveness of Non-nucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Women Previously Exposed to a Single Intrapartum Dose of Nevirapine: A Multi-country, Prospective Cohort Study

In a comparative cohort study, Jeffrey Stringer and colleagues investigate the risk of ART failure in women who received single-dose nevirapine for PMTCT, and assess the duration of increased risk

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.

OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND METHODS: Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following measures: the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36-item short-form health survey (SF-36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale-Revised, risk perception and knowledge. The results of the baseline questionnaire are presented. RESULTS: A total of 432 men completed questionnaires: 98 and 160 had mutations in BRCA1 and BRCA2 genes, respectively, and 174 were controls (familial mutation negative). Participants' perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF-36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status. CONCLUSION: This is the first study to report the psychosocial profile of men with BRCA1/BRCA2 mutations undergoing PCa screening. No clinically concerning levels of general or cancer-specific distress or poor quality of life were detected in the cohort as a whole. A small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support to men seeking PCa screening

Vulnerable Children, Young People, and Families: Policy, Practice, and Social Justice in England and Scotland

This chapter begins by highlighting the rise of vulnerability as a term in social policy, and the three-level approach that is used to examine it. The first level is definitional, examining the possibility of defining vulnerability and vulnerabilities through a consideration of relevant literature and a number of recent policy documents. The second looks at how policy developments in Scotland and England have diverged, particularly since 2010, and how vulnerability has become more central to education policy in England. The third level focuses on practice, presenting research undertaken by the authors into a programme developed to support vulnerable children, young people, and families in Northern England as a case study exemplifying some of the factors affecting the effectiveness of programmes in which schools played an important but not central part. This practice perspective is still too often overlooked in discussions of policy and definition, and it is suggested that its inclusion will contribute to the ongoing debate about both how best to support vulnerable families and the implications for education and social justice

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection. Methods: This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. Findings: This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], p\textless0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p\textless0·0001), American Society of Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p\textless0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major versus minor surgery (1·52 [1·01–2·31], p=0·047). Interpretation: Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery. Funding: National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research

Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin

To assess the extent to which prior hormone therapy modifies the breast cancer risk found with estrogen plus progestin (E + P) in the Women's Health Initiative (WHI) randomized trial. Subgroup analyses of prior hormone use on invasive breast cancer incidence in 16,608 postmenopausal women in the WHI randomized trial of E + P over an average 5.6 years of follow-up. Small but statistically significant differences were found between prior HT users and non-users for most breast cancer risk factors but Gail risk scores were similar. Duration of E + P use within the trial (mean 4.4 years, S.D. 2.0) did not vary by prior use. Among 4311 prior users, the adjusted hazard ratio (HR) for E + P versus placebo was 1.96 (95% confidence interval [CI]: 1.17–3.27), significantly different ( p = 0.03) from that among 12,297 never users (HR 1.02; 95% CI: 0.77–1.36). The interaction between study arm and follow-up time was significant overall ( p = 0.01) and among never users ( p = 0.02) but not among prior users ( p = 0.10). The cumulative incidence over time for the E + P and placebo groups appeared to cross after about 3 years in prior users, and after about 5 years in women with no prior use. No interaction was found with duration ( p = 0.08) or recency of prior use ( p = 0.17). Prior hormone use significantly increased the E + P hazard ratio for larger, more advanced tumors. A safe interval for combined hormone use could not be reliably defined with these data. However, the significant increase in breast cancer risk in the trial overall after only 5.6 years of follow-up, initially concentrated in women with prior hormone exposure, but with increasing risk over time in women without prior exposure, suggests that durations only slightly longer than those in the WHI trial are associated with increased risk of breast cancer. Longer-term exposure and follow-up data are needed